5 Drugs Stocks On The Rise

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 15,368 as of Monday, May 20, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,885 issues advancing vs. 1,048 declining with 118 unchanged.

The Drugs industry currently sits down 0.15 versus the S&P 500, which is up 0.1%. A company within the industry that increased today was Actavis ( ACT), up 2.39. On the negative front, top decliners within the industry include Pharmacyclics Incorporated ( PCYC), down 4.30, Amgen ( AMGN), down 3.34, Allergan ( AGN), down 1.51, Valeant Pharmaceuticals International ( VRX), down 1.39 and Celgene Corporation ( CELG), down 1.27.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Shire ( SHPG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Shire is up $1.80 (1.93) to $95.23 on average volume Thus far, 326,740 shares of Shire exchanged hands as compared to its average daily volume of 569,400 shares. The stock has ranged in price between $94.38-$95.46 after having opened the day at $94.51 as compared to the previous trading day's close of $93.43.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $17.6 billion and is part of the health care sector. The company has a P/E ratio of 30.8, above the S&P 500 P/E ratio of 17.7. Shares are up 1.5% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Shire Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Watson Pharmaceuticals ( WPI) is up $3.15 (2.51) to $128.65 on heavy volume Thus far, 5.4 million shares of Watson Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $126.63-$131.24 after having opened the day at $127.80 as compared to the previous trading day's close of $125.50.

Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products in the United States, western Europe, Canada, Australasia, Asia, South America, and South Africa. Watson Pharmaceuticals has a market cap of $11.0 billion and is part of the health care sector. The company has a P/E ratio of 13.9, below the S&P 500 P/E ratio of 17.7. Shares are down 1.5% year to date as of the close of trading on Friday. Currently there are 16 analysts that rate Watson Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Watson Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Watson Pharmaceuticals Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Herbalife ( HLF) is up $3.96 (8.91) to $48.40 on heavy volume Thus far, 3.0 million shares of Herbalife exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $44.41-$48.62 after having opened the day at $44.49 as compared to the previous trading day's close of $44.44.

Herbalife Ltd., a network marketing company, sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $4.5 billion and is part of the health care sector. The company has a P/E ratio of 10.3, below the S&P 500 P/E ratio of 17.7. Shares are up 34.9% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Herbalife a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Herbalife Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Abbott Laboratories ( ABT) is up $1.18 (3.21) to $37.76 on average volume Thus far, 4.0 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.3 million shares. The stock has ranged in price between $36.87-$37.83 after having opened the day at $36.95 as compared to the previous trading day's close of $36.59.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $57.4 billion and is part of the health care sector. The company has a P/E ratio of 9.6, below the S&P 500 P/E ratio of 17.7. Shares are up 11.7% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Abbott Laboratories Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.43 (0.99) to $43.73 on average volume Thus far, 4.2 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.9 million shares. The stock has ranged in price between $43.35-$44.14 after having opened the day at $43.36 as compared to the previous trading day's close of $43.30.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $70.3 billion and is part of the health care sector. The company has a P/E ratio of 48.1, above the S&P 500 P/E ratio of 17.7. Shares are up 32.9% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 13 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Billionaire Hedge Fund Manager Leon Cooperman Gave His Top 5 Cheap Stocks